6LOX
Crystal Structure of human glutaminase with macrocyclic inhibitor
Summary for 6LOX
Entry DOI | 10.2210/pdb6lox/pdb |
Descriptor | Glutaminase kidney isoform, mitochondrial, (E)-15,22-Dioxa-4,11-diaza-5(2,5)-thiadiazola-10(3,6)-pyridazina-1,14(1,3)-dibenzenacyclodocosaphan-18-ene-3,12-dione (3 entities in total) |
Functional Keywords | protein-inhibitor complex, protein binding |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 4 |
Total formula weight | 236949.40 |
Authors | |
Primary citation | Xu, X.,Wang, J.,Wang, M.,Yuan, X.,Li, L.,Zhang, C.,Huang, H.,Jing, T.,Wang, C.,Tong, C.,Zhou, L.,Meng, Y.,Xu, P.,Kou, J.,Qiu, Z.,Li, Z.,Bian, J. Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site. J.Med.Chem., 64:4588-4611, 2021 Cited by PubMed Abstract: The inhibition of glutaminase 1 (GLS1) represents a potential treatment of malignant tumors. Structural analysis led to the design of a novel series of macrocyclic GLS1 allosteric inhibitors. Through extensive structure-activity relationship studies, a promising candidate molecule () was identified with robust GLS1 inhibitory activity (IC = 6 nM) and high GLS1 binding affinity (SPR, = 24 nM; ITC, = 37 nM). The X-ray crystal structure of the -GLS1 complex was resolved, revealing a unique binding mode and providing a novel structural scaffold for GLS1 allosteric inhibitors. Importantly, clearly adjusted the cellular metabolites and induced an increase in the ROS level by blocking glutamine metabolism. Furthermore, exhibited a similar antitumor activity as . This study adds to the growing body of evidence that macrocyclization provides an alternative and complementary approach for the design of small-molecule inhibitors, with the potential to improve the binding affinity to the targets. PubMed: 33792311DOI: 10.1021/acs.jmedchem.0c02044 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (3.2 Å) |
Structure validation
Download full validation report
